Share Email Print

Proceedings Paper

Use of in vitro OmniPlex libraries for high-throughput comparative genomics and molecular haplotyping
Author(s): Emmanuel Kamberov; Irina Sleptsova; Stephen Suchyta; Eric D. Bruening; William Ziehler; Julie Seward Nagel; John P. Langmore; Vladimir Makarov
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

OmniPlex Technology is a new approach to genome amplification and targeted analysis. Initially the entire genome is reformatted into small, amplifiable molecules called Plexisomes, which represent the entire genome as an OmniPlex Library. The whole genome can be amplified en masse using universal primers; using locus-specific primers, regions as large as 50 kb can be amplified. Amplified Plexisomes can be analyzed using conventional methods such as capillary sequencing and microarray hybridization. The advantages to using OmniPlex as the 'front-end' for conventional analytical instruments are that a) the initial copy number of the analytes can be increased to achieve better signal-to-noire ratio, b) only a single priming site is used and c) up to 20 times fewer biochemical reactions and oligonucleotides are necessary to amplify a large region, compared to conventional PCR. These factors make OmniPlex more flexible, faster, and less expensive than conventional technologies. OmniPlex has been applied to targeted sequencing of human, animal, plant, and microorganism genomes. In addition, OmniPlex is inherently able to haplotype large regions of human DNA to accelerate target discovery and pharmacogenomics. OmniPlex will be a key tool for delivery of improved crops and livestock, new pharmaceutical products, and personalized medicine.

Paper Details

Date Published: 21 June 2002
PDF: 12 pages
Proc. SPIE 4626, Biomedical Nanotechnology Architectures and Applications, (21 June 2002); doi: 10.1117/12.472062
Show Author Affiliations
Emmanuel Kamberov, Rubicon Genomics, Inc. (United States)
Irina Sleptsova, Rubicon Genomics, Inc. (United States)
Stephen Suchyta, Rubicon Genomics, Inc. (United States)
Eric D. Bruening, Rubicon Genomics, Inc. (United States)
William Ziehler, Rubicon Genomics, Inc. (United States)
Julie Seward Nagel, Rubicon Genomics, Inc. (United States)
John P. Langmore, Rubicon Genomics, Inc. (United States)
Vladimir Makarov, Rubicon Genomics, Inc. (United States)

Published in SPIE Proceedings Vol. 4626:
Biomedical Nanotechnology Architectures and Applications
Raymond P. Mariella; Catherine J. Murphy; Michelle Palmer; David A. Dunn; Darryl J. Bornhop; David A. Dunn; Raymond P. Mariella; Catherine J. Murphy; Dan V. Nicolau; Shuming Nie; Michelle Palmer; Ramesh Raghavachari; Darryl J. Bornhop; Ramesh Raghavachari; Shuming Nie; Ramesh Raghavachari, Editor(s)

© SPIE. Terms of Use
Back to Top